Abstract
Regulation of B-cell development and activation is imperative to the myriad of activities that perpetuate humoral immunity. This T-cell dependent immune mechanism often relies upon the maintenance of T-cell tolerance, such that the maturity of the antigen-presentating cell, its function and molecular mimicry are contributing factors. Recent findings have implicated the involvement of the B-cell and their corresponding surface co-receptors in regulating autoimmune disease. One candidate receptor, PECAM-1, has demonstrated the ability to downregulate both B and T-cell signalling pathways. The deletion of PECAM-1 in mice has led to a hyper-responsive B-cell phenotype with abnormal Bcell development. Additionally, in vivo functional studies have found that absence of PECAM-1 results in an increased susceptibility to autoimmune disorders of encephalomyelitis and Type I hypersensitivity reactions. Taken together, these findings indicate that PECAM-1 may have an important role in maintaining B-cell tolerance and regulatory function in preventing the onset of autoimmune disease. Elucidating the mechanisms of PECAM-1 function in autoimmune disorders could facilitate development of novel therapeutics.
Keywords: PECAM-1, autoimmune disease, B-cell, T-cell
Current Pharmaceutical Design
Title: Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Volume: 10 Issue: 2
Author(s): Mae-Xhum Wong and Denise E. Jackson
Affiliation:
Keywords: PECAM-1, autoimmune disease, B-cell, T-cell
Abstract: Regulation of B-cell development and activation is imperative to the myriad of activities that perpetuate humoral immunity. This T-cell dependent immune mechanism often relies upon the maintenance of T-cell tolerance, such that the maturity of the antigen-presentating cell, its function and molecular mimicry are contributing factors. Recent findings have implicated the involvement of the B-cell and their corresponding surface co-receptors in regulating autoimmune disease. One candidate receptor, PECAM-1, has demonstrated the ability to downregulate both B and T-cell signalling pathways. The deletion of PECAM-1 in mice has led to a hyper-responsive B-cell phenotype with abnormal Bcell development. Additionally, in vivo functional studies have found that absence of PECAM-1 results in an increased susceptibility to autoimmune disorders of encephalomyelitis and Type I hypersensitivity reactions. Taken together, these findings indicate that PECAM-1 may have an important role in maintaining B-cell tolerance and regulatory function in preventing the onset of autoimmune disease. Elucidating the mechanisms of PECAM-1 function in autoimmune disorders could facilitate development of novel therapeutics.
Export Options
About this article
Cite this article as:
Wong Mae-Xhum and Jackson E. Denise, Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders, Current Pharmaceutical Design 2004; 10 (2) . https://dx.doi.org/10.2174/1381612043453504
DOI https://dx.doi.org/10.2174/1381612043453504 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design NLRP3 Inflammasome Activation Leads to Epileptic Neuronal Apoptosis
Current Neurovascular Research On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Anti-Aggressive, Brain Neurotransmitters and Receptor Binding Study of Fumaria indica in Rodents
Current Psychopharmacology The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry The Classic Basic Protein of Myelin – Conserved Structural Motifs and the Dynamic Molecular Barcode Involved in Membrane Adhesion and Protein-Protein Interactions
Current Protein & Peptide Science Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology Etiological and Biological Aspects of Cigarette Smoking in Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Autoantibody Reaction to Myelin Basic Protein by Plasma Parvovirus B19 IgG in MS Patients
Protein & Peptide Letters Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy